Storia in 10 fonti

Novartis acquires British start-up Myricx Bio

The Swiss pharma giant will pay $1.1 billion (CHF883 million) to acquire Myricx Bio, which is developing antibody-drug conjugates for various types of solid tumours.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

swissinfo.chStai leggendo1 mese fa

Novartis acquires British start-up Myricx Bio

The Swiss pharma giant will pay $1.1 billion (CHF883 million) to acquire Myricx Bio, which is developing antibody-drug conjugates for various types of solid tumours.

originale

Timeline cronologica

lunedì 6 luglio 2026·biopharmadive.com
Novartis to acquire ADC developer in a deal worth up to $1.5B
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
lunedì 6 luglio 2026·morningstar.com
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

Novartis acquires British start-up Myricx Bio

Confronto fonti

Novartis acquires British start-up Myricx Bio

Timeline cronologica

Novartis to acquire ADC developer in a deal worth up to $1.5B

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)

Patent cliff fuels Novartis' $1.5bn swoop for London biotech

Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari

London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN

Aussie super funds hit the jackpot in $2b UK biotech deal

Correction to Novartis Article

Novartis: rileva gruppo biotecnologie Myricx Bio per 1,1 mld $

Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN

Novartis acquires British start-up Myricx Bio

Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform

Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari

Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)

Patent cliff fuels Novartis' $1.5bn swoop for London biotech